Tackling Barriers to Optimal Adult ADHD Management: Stigma, Co-Morbid Disorders, and Stimulant Misuse and Diversion
Greg Mattingly, MD
Associate Clinical Professor
Washington University School of Medicine
President, Midwest Research Group
St. Louis, Missouri
Joel L. Young, MD
Rochester Center for Behavioral Medicine
Clinical Associate Professor of Psychiatry
Wayne State University School of Medicine
This session was previously presented at Psych Congress 2021. If you claimed credit for this session at Psych Congress 2021, you are not eligable to claim credit for this session again.
Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Global Company.
For questions regarding this educational activity, please call 609-371-1137 or email firstname.lastname@example.org.
This activity is designed for psychiatrists, primary care physicians, psychologists, nurse practitioners, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.
After participating in this activity, learners should be better able to:
- Implement strategies for more timely and accurate diagnosis of individuals with attention-deficit/hyperactivity disorder (ADHD)
- Evaluate the pharmacological properties of stimulants approved for treatment of adult ADHD, in addition to the latest clinical data on patient treatment response
- Incorporate multidisciplinary perspectives and evidence-based strategies into development of individualized, patient-centric treatment plans that support medication adherence for adult patients with ADHD
- Implement state-of-the-art care models to address barriers to optimal ADHD care
To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: December 15, 2021
Expiration Date: December 31, 2022
Estimated Time to Complete: 90 minutes
There is no fee associated with this activity.
NACCME would like to thank the following company who has supported "Tackling Barriers to Optimal Adult ADHD Management: Stigma, Co-Morbid Disorders, and Stimulant Misuse and Diversion" through educational grant support: Takeda Pharmaceuticals U.S.A., Inc.
In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates this internet enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education internet enduring activity awards 1.5 contact hours.
American Academy of Nurse Practitioners National Certification Program accepts 1.5 AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.5 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.
As a Jointly Accredited Organization, North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content. Variable credit for partial attendance may not be awarded. Full attendance is required for all CE activities.
Instructional Level: Advanced
This activity will award 1.5 continuing education credits. Psychologists should claim only the credit commensurate with the extent of their participation in the activity.
As a Jointly Accredited Organization, NACCME is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course mau be accepted for continuing education credit. NACCME maintains responsibility for this course. Social workers completing this course receive 1.5 advanced continuing education credits.
USE OF PROPRIETARY NAMES
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
In accordance with our disclosure policies, NACCME is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.
Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:
- Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
- Any investigational, off-label, or non-FDA approved content or discussion
NACCME has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.
Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:
- All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
- Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.
The faculty has reported the following:
Dr. Mattingly: Consultant—AbbVie, Acadia Pharmaceuticals, Alkermes, Inc., Axsome Therapeutics, Corium, Eisai, Ironshore Pharmaceuticals & Development, Inc., Intra-Cellular Therapies, Inc., Janssen Pharmaceuticals, Lundbeck, Neos Therapeutics, Inc., Neurocrine Biosciences, Otsuka Pharmaceutical, Redax, Roche Pharma, Rhodes Pharmaceuticals, Sage Therapeutics, Shire, Sunovion, Supernus Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceuticals, Tris Pharma Inc.; Grant/Research Support—AbbVie, Acadia Pharmaceuticals, Alkermes, Inc., Avanir Pharmaceuticals Inc, Axsome Therapeutics, Boehringer Ingelheim, Emalex Biosciences, Janssen Pharmaceuticals, Medgenics, NLS1 Pharma AG, Redax, Roche Pharma, Sage Therapeutics, Shire, Sunovion, Supernus Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceuticals; Speakers Bureau—AbbVie, Alkermes, Inc., Corium, Eisai, Janssen Pharmaceuticals, Lundbeck, Neurocrine Biosciences, Otsuka Pharmaceutical, Sunovion, Supernus Pharmaceuticals, Takeda Pharmaceutical, Tris Pharma Inc.
Dr. Young: Advisory Board—Alkermes, Inc., Corium, Noven Pharmaceuticals, Inc.; Grant/Research Support—Janssen Pharmaceuticals, Otsuka Pharmaceutical; Speakers Bureau—Alkermes, Inc., Ironshore Pharmaceuticals, Janssen Pharmaceuticals, Otsuka Pharmaceutical, Supernus Pharmaceuticals.
William C. Torrey, MD
Professor of Psychiatry
Geisel School of Medicine
Lebanon, New Hampshire
Douglas Noordsy, MD
Clinical Professor Director of Lifestyle Psychiatry, Department of Psychiatry & Behavioral Sciences
Stanford University School of Medicine
Palo Alto, California
Dr. Torrey and Dr. Noordsy have disclosed no relevant financial relationship with any ineligible company (commercial interest).
Andrew Penn, RN, MS, NP, CNS, APRN-BC (nurse planner)
Associate Clinical Professor
University of California, San Francisco
San Francisco, California
Mr. Penn: Grant/Research Support—Usona Institute; Salary—Usona Institute.
NACCME planners and staff include Meaghan Benci, Samantha Conforti, Raquel Gaerlan, Kathleen Hines, Mary Johnson, Gina Rescinito, Randy Robbin, Greaton Sellers, Michelle Stewart, and Kelly Sweeney.
No NACCME planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).
North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2021 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at email@example.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers, Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at firstname.lastname@example.org or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.